<?xml version="1.0" encoding="UTF-8"?>
<p>A lingering criticism of plant-based production platforms has been the absence of approved human products in the USA after 25 years of active research and development [
 <xref ref-type="bibr" rid="CR0008125">125</xref>]. Excitingly, this last barrier has been overcome by the recent approval of a plant-produced glucocerebrosidase (commercial name: ELEYSO
 <sup>TM</sup>) by the FDA for treating Gaucher disease, heralding a new era in the field of plant-made pharmaceutics [
 <xref ref-type="bibr" rid="CR000831">31</xref>]. We speculate that plant-based production systems will offer a superior scalability, safety, time and cost-saving benefits for NoV VLP manufacturing.
</p>
